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Abstract
Importance—There are well-documented racial disparities in outcomes for African American 
patients with clear cell renal cell carcinoma (ccRCC). Despite a dramatic improvement in overall 
survival in white patients since the advent of targeted therapy, survival for African Americans with 
advanced ccRCC has not changed. There is little known about potential racial differences in tumor 
biology of ccRCC.
Objective—To determine if there are racial differences in the somatic mutation rate and gene 
expression of ccRCC tumors from white and African American patients.
Design, Setting, and Participants—Overall, 438 patients with ccRCC were identified 
through The Cancer Genome Atlas (TCGA) clear cell kidney (KIRC) dataset (419 white and 19 
African American patients). The GSE25540 dataset containing 135 patients (125 white and 10 
African American patients) was used for validation. Tumor samples were collected from numerous 
cancer centers and were examined for racial differences in somatic mutation rates and RNA 
expression. Racial differences in somatic mutation rates and RNA expression were examined.
Main outcomes and Measures—The comparison of somatic mutation rates and differences in 
RNA expression in white and African American patients with ccRCC.
Results—Overall, 419 ccRCC tumor data sets from non-Hispanic white patients and 19 from 
non-Hispanic African American patients were identified through the publically available TCGA 
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KIRC data set, and a validation set of 125 white and 10 African American ccRCC patient tumors 
was identified from the publicly available GSE25540 data set. African American patients were 
significantly less likely than white patients to have VHL mutations (2 of 12 [17%] vs 175 of 351 
[50%], respectively; P = 04) and were enriched in the ccB molecular subtype (79% in African 
American vs 45% in white patients; P = 005), a molecular subtype that carries a worse prognosis. 
It was found that RNA expression analysis revealed relative down-regulation of hypoxia-inducible 
factor (HIF) and vascular endothelial growth factor (VEGF)-associated pathways in African 
American patients compared with white patients.
Conclusions and Relevance—African American patients have less frequent VHL 
inactivation, are enriched in the ccB molecular subtype, and have decreased up-regulation of HIF-
associated gene signatures than white patients. These genomic differences would predict decreased 
responsiveness to VEGF-targeted therapy and are a biologically plausible contributing factor to the 
worse survival of African American patients with ccRCC, even in the targeted therapy era.
Renal cell carcinoma (RCC) is the eighth most commonly diagnosed cancer in the United 
States. It accounts for nearly 64000 new cancer cases and over 13 000 deaths per year in the 
United States alone.1 Multiple studies from the pretargeted therapy era demonstrate that 
African American patients with RCC have inferior overall survival compared with white 
patients regardless of age, sex, stage, histologic subtype, or surgical treatment.2-4 Despite 
this documented survival disparity, there is no data examining genomic or transcriptomic 
differences of clear cell RCC (ccRCC) in African American patients vs white patients.
The last decade has produced a wealth of knowledge about the molecular drivers of RCC, 
including the comprehensive molecular characterization of ccRCC by The Cancer Genome 
Atlas (TCGA).5 A hallmark event in the development of ccRCC is loss of heterozygosity of 
the von Hippel-Lindau (VHL) tumor suppressor gene. VHL inactivation occurs at a rate of 
52% to 82% in sporadic ccRCC5 and leads to stabilization of the α subunit of the hypoxia-
inducible factor (HIF) family of transcription factors. Stabilization of HIFα subunits results 
in their heterodimerization with HIFβ subunits and a transcriptionally active complex whose 
target genes are intimately involved in tumor angiogenesis. The vascular endothelial growth 
factor (VEGF) pathway in particular is a key transcriptional HIF target and is targeted by a 
number of the currently US Food and Drug Administration-approved therapies. In addition, 
several other genes, such as PBRM1, SETD2, and BAP1, are also mutated in ccRCC patient 
tumors.6 Herein, we investigate potential genetic differences in ccRCC that are associated 
with race.
Methods
The Cancer Genome Atlas and Validation Data and Analysis
RNA sequencing, somatic mutation, and copy number data from the TCGA kidney clear cell 
(KIRC) data set were downloaded from the publically available TCGA data portal (https://
tcga-data.nci.nih.gov/tcga/), and somatic mutation data was downloaded from an 
independent and publicly available data set from Peña-Llopis et al6 (GSE25540 data set).
The TCGA RNaseq data set was log2 transformed and median-centered. Two-class 
significance analysis of microarrays (using 2-fold change and false discovery rate = 0) was 
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performed to generate race-specific gene lists.7 The significant genes and corresponding fold 
changes as determined by significance analysis of microarrays were analyzed by Ingenuity 
Pathway Analysis (Ingenuity Systems) for predicted pathway activation and/or inhibition. 
Gene Set Enrichment Analysis (Broad Institute) was performed comparing ccRCC tumors 
from African American patients vs white patients (ethnicity defined by the TCGA) against 
Molecular Signature Database c2.all.v4.0. The mutations in the 9 most commonly mutated 
genes—VHL, PBRM1, SETD2, KDM5C, PTEN, BAP1, MTOR, TP53, and PI3KCA7—
were analyzed between African American patients and white patients. Patients were then 
classified into the previously described RNA subtypes of ccRCC—ccA and ccB—based on 
patterns of differential gene expression using prediction analysis of microarray.8,9
Statistical Analysis
Differences in somatic mutation rates by race were compared using χ2 or Fisher exact test 
where applicable. Fisher exact test was used to compare prevalence of the ccA and ccB 
molecular subtypes between races.
Results
We first investigated whether there are racial differences in the mutational spectrum of 
ccRCC tumors comparing data from African American patients (n = 19) and white patients 
(n = 419) from the TCGA ccRCC KIRC data set. Overall, 175 of 351 (50%) white patients 
had VHL mutations, whereas 2 of 12 (17%) African American patients had VHL mutations 
(P = .04) (Figure 1A) (eTable 1 in the Supplement). In contrast, there were no racial 
differences in the mutational frequency of other TCGA KIRC–defined significantly mutated 
genes (Figure 1A) (eTable 1 in the Supplement). These results were validated for VHL, 
PBRM1 and BAP1 in an independent data set verifying the lower prevalence of VHL 
mutation in African American patients (Figure 1B) (eTable 1 in the Supplement)6
Given the lower frequency of VHL mutations in African American patients, we investigated 
the RNA expression of the VEGF ligands and VEGF receptors to evaluate for downstream 
effects of VHL loss. In the TCGA KIRC data set, 419 white patients and 19 African 
American patients were available for analysis. In the TCGA data set, African American 
patients had significantly lower expression of the VEGFA ligand (eFigure 1A in the 
Supplement), as well as the FLT-1 (VEGFR1) and KDR (VEGFR2) receptors (eFigure 1B in 
the Supplement). Furthermore, significance analysis of microarrays and subsequent 
ingenuity pathway analysis of upstream regulators predicted that numerous genes associated 
with HIF (EPAS1, HIF1A, ARNT, and CREB1) transcriptional regulation were up-regulated 
in white patients (eTable 2 in the Supplement). Finally, several VEGF and HIF signatures 
were negatively enriched in African American patients as determined by Gene Signature 
Enrichment Analysis (eFigure 3 and eTable 3 in the Supplement). In aggregate, these 
findings indicate distinct differences in the biology of ccRCC in African American patients 
compared with white patients and suggest that ccRCC in African American patients may be 
less dependent upon HIF and VEGF signaling.
Clear cell renal cell carcinoma is a heterogenous disease that can be classified into 2 distinct 
molecular subtypes, ccA and ccB,8 with the ccB subtype associated with a worse survival.8,9 
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Classification of the TCGA KIRC tumors into ccA and ccB subtypes showed that African 
Americans had significant enrichment for the ccB subtype (15 of 19 [79%] African 
American patients have the ccB subtype compared with 190 of 419 [45%] white patients; P 
= 005) (Figure 2A) (eFigure 3 in the Supplement) and in general had high correlation to the 
ccB centroid (Figure 2B). This predominance of the ccB subtype in African American 
patients and its association with worse survival suggests that the intrinsic biology of ccRCC 
in African American patients may contribute to their well-documented worse survival 
outcomes.
Discussion
This is the first report to our knowledge to examine genomic differences between ccRCC in 
African American patients vs white patients. Our results indicate that ccRCC tumors from 
African American patients exhibit a lower rate of VHL mutation and a correspondingly 
lower level of HIF and VEGF pathway activation. We therefore postulate that a significantly 
larger proportion of tumors from African American patients may have a HIF-independent 
and VEGF-independent propensity for aggressiveness, resulting in resistance to the 
commonly used VEGF-targeted therapies. While our results point toward a biologic 
rationale for the lack of improvement in survival of African American patients since the 
advent of targeted therapy,10 we recognize that there are also a host of other potential factors 
(eg, access to health care, time to diagnosis, and appropriate treatment) that likely contribute 
to the racial disparities seen in advanced ccRCC. Nonetheless, the results presented herein 
provide insight into the potential role that genomic variation plays in the disparity observed 
between races.
Finally, why African American patients with ccRCC have less frequent VHL mutations is 
unclear. One possibility is that the development of ccRCC in African Americans may have a 
different etiology. For example, patients with end-stage renal disease have a higher incidence 
of RCC than the general population,11 and ccRCC tumors developing in patients with end-
stage renal disease have lower rates of 3p loss or VHL mutation.12,13 Given higher rates of 
end-stage renal disease in African Americans (likely a consequence of a higher incidence 
and earlier onset of hypertension),14 it is plausible that the lower rate of VHL mutation in 
ccRCC tumors from African Americans may be the result of increased rates of end-stage 
renal disease. Comprehensive population-based studies will be needed to define correlations 
between race and etiologic heterogeneity.
Conclusions
Despite an impressive improvement in overall survival in white patients since the advent of 
VEGF pathway–targeted therapy, the survival for African American patients with advanced 
ccRCC has not changed. We present evidence of distinct differences in tumor biology 
between African American patients and white patients that would predict for less 
responsiveness to VEGF-targeted therapy. While this is a plausible biologic explanation for 
the lack of improved survival in African American patients, it is likely that disparities in 
health care delivery contribute to survival differences as well.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
Question
Are there genomic differences between clear cell renal cell carcinomas (ccRCC) that 
arise in African American patients and white patients that may contribute to the disparity 
in survival outcomes observed between races?
Findings
Using data from the The Cancer Genome Atlas clear cell kidney project, we found that 
African American patients have a significantly lower rate of mutations of the von Hippel-
Lindau tumor suppressor gene, as well as decreased hypoxia-inducible factor activation. 
In addition, African American patients are enriched for a previously defined RNA 
subtype (ccB) that is associated with worse survival outcomes.
Meaning
There are distinct racial differences in the biology of ccRCC tumors that may partially 
explain the well-documented racial disparity in survival outcomes of African American 
patients with advanced ccRCC.
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Figure 1. Gene Mutations in Clear Cell Renal Cell Carcinoma Tumors by Data Set Source and 
Race
A, Mutations in significantly mutated genes according to the The Cancer Genome Atlas 
kidney clear cell data sets are shown by race, B, Frequency of VHL mutations in an 
independent data set6 are shown by race.
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Figure 2. Incidence and Correlation to Centroid of Clear Cell Renal Cell Carcinoma Tumor 
Subtype
A, Visual representation of the incidence of ccA and ccB RNA subtypes of clear cell renal 
cell carcinoma tumor subtype by race, B, Distance and correlation to centroid of tumor 
subtype (ccA and ccB) by race.
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